Morningstar

Ensysce Biosciences Inc Ordinary Shares ENSC

Stock XNAS Rating as of Oct 2, 2026

News

Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA

ACCESS Newswire Sep 24, 2026, 12:00:00 PM
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation

ACCESS Newswire Sep 15, 2026, 1:15:00 PM
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

ACCESS Newswire Sep 14, 2026, 12:00:00 PM
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

ACCESS Newswire Sep 2, 2026, 12:30:00 PM
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

ACCESS Newswire Aug 31, 2026, 12:30:00 PM
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium

ACCESS Newswire Aug 20, 2026, 12:00:00 PM
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

ACCESS Newswire Aug 13, 2026, 8:15:00 PM
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

ACCESS Newswire Aug 6, 2026, 12:00:00 PM
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

ACCESS Newswire Jul 14, 2026, 12:00:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.